Mavacamten 2026 Update

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
As of early 2026, Mavacamten is a fully approved, first-in-class cardiac myosin inhibitor. It is widely authorized for use in over 50 countries across five continents. Mavacamten is approved for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III hypertrophic obstructive cardiomyopathy (HOCM). Read More: https://johnsonfrancis.org/professional/what-is-the-current-approval-status-of-mavacamten/
Categoria
Cardiology
Commenta per primo questo video.

Prossimo